Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30721764 | 1.00 | NR1H2 (0.48) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL16053073 | 1.00 | NR1H2 (0.48) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL17310897 | 1.00 | NR1H2 (0.48) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL16930998 | 0.93 | NR1H2 (0.44) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL4737272 | 0.93 | NR1H2 (0.44) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL1572930 | 0.93 | NR1H2 (0.44) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL16930999 | 0.93 | NR1H2 (0.44) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL30456208 | 0.93 | NR1H2 (0.44) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL29812758 | 0.93 | NR1H2 (0.44) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 | |
| SCHEMBL19462434 | 0.93 | NR1H2 (0.44) | NR1H2PDE4BUSP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240118281-A1 | ANTICANCER COMPOUNDS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-04-11 | — | — | US | disclosed |
| WO-2022150754-A2 | ANTICANCER COMPOUNDS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240118281-A1 | ANTICANCER COMPOUNDS AND USES THEREOF | MKI67, TP53, PCNA | NR1H2 2200/4885PDE4B 3770/4885USP2 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.